Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2022.06.24

Sai Life Sciences expands UK footprint four-fold at Alderley Park

Sai Life Sciences expands UK footprint four-fold at Alderley Park

  • India-headquartered molecular research specialists scale UK R&D capabilities in North West
  • Expansion follows rapid business growth – with >50 new hires over the last two years

One of the fastest growing global contract research, development and manufacturing (CRO-CDMO) businesses, Sai Life Sciences, has expanded its existing base at Alderley Park – part of Bruntwood SciTech’s national network of innovation districts – in response to continuing growth.

With a four-fold increase in floor space from 5,000 to 20,000 sq. ft over the last 2 years, Sai Life Sciences’ expansion within the Park’s Mereside Campus includes the addition of a new chemistry and analytical lab, as well as an increase in its fume cupboard provision from 24 to 80. Other capability additions include Integrity 10 parallel screening tool, Open Access GCMS, Open Access Chiral HPLC, Open Access 400 MHz NMR, physical properties analytical equipment (DSC/TGA, XRPD, PSD) and LCMS with accurate mass.

The full-service CRO-CDMO – which works globally with innovative biotech and pharma companies to accelerate the discovery, development and manufacture of complex small molecules for the creation of new medicines –moved to Alderley Park in 2020 to establish its first European hub. Sai Life Sciences’ Alderley Park site has since grown to become a reliable partner to many innovator companies across the world, providing high quality chemistry, non GMP delivery, and successful technology transfer to its sites in India for scale-up. Currently, work is underway to also set-up a GMP Kilo Lab at the site by Q4 2022.

Dr Kath Mackay, Director of Life Sciences at Bruntwood SciTech, a partnership between property company Bruntwood and Legal & General, said: “Sai Life Sciences’ rapid expansion since first establishing its European presence here demonstrates just how much of a hotbed Alderley Park, and the UK more broadly, is for high-growth life sciences businesses. Meeting the very real demand that our companies have for grow-on space is something we are committed to meeting, and is why we’re focused on continuing to invest in our lab provision across our network.

“Sai Life Sciences’ expansion also speaks to the value in joining an established, thriving knowledge ecosystem. We see time and again the power in being located within a cluster like Alderley Park – particularly when entering a new market from overseas.”

Tuneer Ghosh, Senior Vice President and Head of CMC Business Development at Sai Life Sciences, said: “Our further UK expansion is testament to the strength of the life science community at Alderley Park. With a growing interest from innovator companies across the UK, Europe and US, this expansion in our facilities along with our top-notch scientific team, will help us better serve the growing demand for high quality process chemistry."

Credit: https://www.alderleypark.co.uk/

Share article

More News

2026.03.10

AI-driven retrosynthesis integrated into Discovery Chemistry

Sai Life Sciences has entered into a collaboration with Chemical.AI, a technology company specialising in computer-aided synthesis design, to integrate an AI-driven retrosynthesis platform into its Discovery Chemistry workflows. The integration enables medicinal chemists to evaluate synthetic routes more rapidly and explore a broader set of feasible pathways during early-stage drug discovery. Retrosynthesis is a […]
Read more

2026.03.10

Structural Biology capabilities launched with X-Ray Crystallography

Sai Life Sciences has introduced integrated structural biology capabilities with the establishment of X-ray protein crystallography workflows to support structure-based drug discovery programs. The platform encompasses end-to-end protein engineering capabilities, including construct design, gene synthesis, and in-house recombinant protein expression and purification. These foundational steps enable generation of high-quality protein material suitable for structural and […]
Read more

2026.03.09

New Medicinal Chemistry block set for inauguration in Hyderabad

A new Medicinal Chemistry block, Unit VIII, is set for inauguration at IKP, Genome Valley, Hyderabad, expanding discovery capacity to meet growing program demand. The four-floor facility spans approximately 100,000 sq. ft. and is designed to support large, multi-disciplinary project teams. It accommodates more than 200 fume hoods and includes a tightly integrated analytical laboratory […]
Read more

2026.03.09

AI-enabled production and material planning platform implemented

Over the past several months, focused AI pilot initiatives have been conducted across operations to evaluate practical applications that strengthen execution. One such initiative is now live across the network: Optimus, an integrated AI-enabled production and material planning platform, implemented at the end of December 2025. Optimus consolidates capacity planning, equipment allocation, and material availability […]
Read more

2026.03.09

Commercial-scale Photo Flow Chemistry successfully executed in Bidar

Commercial-scale flow chemistry has been successfully executed at our API manufacturing site in Bidar for a late-phase program supporting a US-based innovator. This execution builds on prior investments in continuous processing infrastructure at the site, including a 3-litre photo flow reactor equipped with a monochromatic blue LED light source. The platform enables controlled photochemical transformations […]
Read more